Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of Alpharadin® in Breast Cancer Patients With Bone Dominant Disease no Longer Considered Suitable for Hormone Therapy
This study is ongoing, but not recruiting participants.
Study NCT01070485   Information provided by Algeta ASA

First Received on February 17, 2010.   Last Updated on October 4, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Bone Metastases
Additional conditions recognized in this trial
Bone Marrow Diseases
Bone Neoplasms
Breast Neoplasms
Neoplasm Metastasis
More general conditions related to this trial
Bone Diseases
Breast Diseases
Hematologic Diseases
Musculoskeletal Diseases
Neoplasms
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Skin Diseases
Interventions listed in this trial
Radium-223 chloride (Alpharadin)
Sponsors listed in this trial
Algeta ASA
Bayer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services